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The clinical practice guidelines on diagnosis and management of high blood pressure in 
children and adolescents have been periodically modified and updated since the original 
publication in 1977.1  Since the last pediatric blood pressure guideline was published in 2004, 
known as the Fourth Report,2  the literature on child BP and hypertension has expanded 
considerably.  There has been a recognized need to update the Fourth Report for several years.  
However, the National Heart, Lung, and Blood Institute (NHLBI) who sponsored previous 
pediatric BP guidelines announced that NHLBI would no longer sponsor development of new 
clinical guidelines.3  Subsequently, in 2014 the American Academy of Pediatrics (AAP) agreed 
to sponsor development of a new pediatric BP clinical practice guideline (CPG). The new CPG 
for screening and management of high BP in children and adolescents was recently published 
in Pediatrics.4 This CPG was developed using the rigorous evidence-based approach 
recommended by the Institute of Medicine in 2011.5 This methodology was consistent with 
recent NHLBI recommendations on development of CPGs for cardiovascular disease.3  The 
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new pediatric hypertension CPG contains several modifications from the  previous guideline to 
guide clinicians in diagnosis and management of elevated BP and hypertension in children and 
adolescents. This summary describes those changes made since the 2004 Fourth Report. 
 
 The childhood BP database used to develop normative BP data and BP tables in the 
previous pediatric BP CPGs included overweight and obese children. Recently,  this BP 
database was reanalyzed by Rosner et al.6 who found that when overweight and obese children 
were excluded the BP levels, adjusted for sex, age, and height, were 2 to 3 mm Hg lower than 
the values in the Fourth Report.  Due to the strong association of excess adiposity with higher 
BP throughout childhood, it was determined that normative reference data and BP tables should 
be based on normal weight (body mass index [BMI] <85th %) children and adolescents.  The 
new tables now provide systolic and diastolic BP levels on normal weight children and 
adolescents according to age, sex, and height at the 50th, 90th, and 95th percentiles, and the 
95th+12 mm Hg to denote stage 2 hypertension.  Similar to the previous BP tables in the Fourth 
Report, the new BP tables are precise. However, also similar to Fourth Report tables, they are 
complex and cumbersome to use in clinical practice. Because it was evident that the detailed 
tables may have contributed to under-detection of childhood hypertension in clinical practice,7 a 
tool to facilitate detection has been added in the new CPG. It was also recognized that 
automated BP devices are frequently used in clinical practices, while the BP tables are based 
on auscultation measurement. To facilitate detection of abnormal BP levels in clinical practices 
a simplified, easy to use, table that lists systolic and diastolic BP level at the 90th percentile by 
age and sex is provided for screening purposes in the 2017 CPG. The table uses the BP values 
at the 90th percentile for children at the 5th percentile for height, which captures all children with 
BP >90th percentile from shortest to tallest at each age. A BP measurement at or above the 90th 
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percentile should be repeated and if replicated warrants further measurement by auscultation 
for confirmation of elevated BP or hypertension.   
 
  Since publication of the first pediatric hypertension clinical guideline in 19771 the 
definition of hypertension in childhood has been systolic and/or diastolic BP > the 95th percentile 
which represents the top portion of the normative BP distribution by age and sex. The definition 
was subsequently adjusted to BP > the 95th percentile according to age, sex, and height 
percentile.2  This statistical definition is due to absence of outcome data. Without outcome data, 
it has not been possible to link a BP level in childhood with risk for hypertension related 
cardiovascular events later in life. This definition of hypertension remains the same for children 
<13 years of age which is average systolic and/or diastolic BP >95th percentile on the new BP 
tables. The term “prehypertension” has been changed to “elevated BP” which is defined as 
average systolic or diastolic BP >90th and <95th percentile. The definitions of elevated BP and 
hypertension have changed for adolescents. The 95th percentile for systolic BP among 
adolescents is close to 130 mm Hg.  Therefore, beginning at age 13 years, the definition of 
elevated BP and hypertension are now numerical values. This change from a percentile to a 
numerical definition serves to simplify recognition of hypertension in adolescents.  These new 
definitions of elevated BP and hypertension in adolescence are also identical with the new 
definitions of abnormal BP in the CPG for hypertension in adults developed by the American 
Heart Association and the American College of Cardiology.8 The BP definitions for children and 
adolescents are summarized as follows: 
 
Children <13 years: 
 Normal BP = systolic and diastolic BP <90th percentile 
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 Elevated BP = systolic and/or diastolic BP >90th to <95th percentile 
 Hypertension = systolic and/or diastolic BP >95th percentile 
  Stage 1= systolic and/or diastolic >95th to <95th percentile + 12 mm Hg 
  Stage 2 = systolic and/or diastolic >95th percentile + 12 mm Hg 
 
Adolescents >13 years: 
 Normal BP = systolic and diastolic BP <120/<80 mm Hg 
 Elevated BP = systolic and diastolic BP >120/<80 to 129/<80 mm Hg 
 Hypertension = systolic and/or diastolic BP >130/80 mm Hg 
  Stage 1 = systolic and/or diastolic BP >130/80 to 139/89 mm Hg 
  Stage 2 = systolic and or diastolic BP >140/90 mm Hg 
 
BP measurements in children and adolescents are now recommended only during routine 
health care visits, unless the patient has chronic conditions requiring more than preventive care 
and associated with abnormal BP such as obesity, kidney disease, heart disease, or diabetes. 
The diagnosis of hypertension continues to be based on abnormal BP on three separate clinical 
visits, unless the patient is symptomatic.  BP measurement by auscultation remains the 
preferred method for confirmation of abnormal BP status because the normative BP tables are 
based on auscultated BP measurements.   
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Following publication of the 2004 Fourth report, considerable advancement has 
developed in application of 24-hour ambulatory blood pressure monitoring (ABPM) in children 
and adolescents.9  The 2017 pediatric CPG now recommends ABPM for confirmation of 
abnormal BP status in several clinical situations. These include confirmation of the diagnosis of 
hypertension in patients with repeated abnormal BP measurements, identification of white coat 
hypertension, and detection of masked hypertension.  ABPM has also been found useful in 
identifying masked hypertension in children with a history of coarctation of the aorta, 
hypertensive target organ damage (TOD) in children with chronic kidney disease; and 
evaluating BP status in pediatric heart and kidney transplant recipients. Evaluating treatment 
effectiveness in patients receiving antihypertensive therapy is another useful application of 
ABPM included in the 2017 CPG recommendations.4 The recommendation to utilize ABPM to 
develop additional clinical information in children and adolescents with abnormal BP is in line 
with the United States Preventive Services Task Force recommendation for hypertensive 
adults.10  Although adult guidelines also recommend home BP monitoring as an alternative to 
ABPM for confirmation of hypertension, the evidence on home BP monitoring is limited in 
children and adolescents.  Thus, home BP monitoring for the purpose of determining BP status 
was not recommended in the 2017 CPG. It was also recognized that ABPM may not be 
available to many primary care clinicians, which would necessitate reliance on repeated clinic 
BP measurements or referral to a pediatric subspecialist. 
 
When the 2004 Fourth Report was published, it was recognized that TOD could be 
detected in some hypertensive children and adolescents. As part of the evaluation of a pediatric 
patient with hypertension, the 2004 Fourth Report included a recommendation to obtain an 
echocardiogram, to assess for possible left ventricular hypertrophy (LVH), defined as left 
ventricular mass index (LVMI) >51.7 g/m2.7.  However, since 2004 several publications have 
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 7 
reported LVH among some prehypertensive pediatric patients,11 and an independent effect of 
obesity on cardiac mass,12 and different approaches to quantifying cardiac mass.  These 
developments led to different recommendations in the 2017 CPG for pediatric patients.  The 
2017 CPG retained the LVH definition of LVMI >51.7 g/m2.7 for children and adolescents over 8 
years of age, but states that LVH could also be defined as Left ventricular mas (LVM) >115 
g/body surface area in boys and >95 g/body surface area in girls. Additional cardiac parameters 
of concentric LVH and decreased LV ejection fraction were also defined and added to the 2017 
CPG. It is recognized by the 2017 CPG authors that further study is needed to determine the 
clinical significance of a LVMI >95th percentile (of LVMI normative data) but <51.7 g/m2.7, as well 
as the most appropriate cardiac mass index.   
 
Another change in the 2017 CPG recommendation is the timing of the echocardiogram.  Rather 
than obtaining an echocardiogram as part of the hypertension evaluation, the 2017 CPG 
recommends performing an echocardiogram when pharmacological treatment is considered, as 
it would facilitate decision making on drug therapy.  Repeat echocardiogram may also be 
considered to monitor identified LVH or reduced LV ejection fraction on the initial 
echocardiogram. A repeat echocardiogram can also be indicated in patients on whom the initial 
echocardiogram was normal but have secondary hypertension or insufficient BP reduction of 
secondary hypertension or stage 2 hypertension. 
 
There is strong evidence in support of antihypertensive therapy in adult hypertensive 
patients for the purpose of primary prevention of subsequent cardiovascular events.  Similar 
evidence in pediatric hypertensive patients is lacking. Therefore, a major emphasis has been, 
and continues to be, on non-pharmacologic, or lifestyle changes in diet, physical activity, and 
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 8 
weight control.  Indications for pharmacologic therapy in pediatric hypertensive patients continue 
to be conservative in the 2017 CPG and include persistent hypertension despite lifestyle 
modification especially with an abnormal echocardiogram, stage 2 hypertension without a 
modifiable risk factor, and any stage of hypertension in patients with diabetes or chronic kidney 
disease.  The 2017 CPG is less specific with recommendations on management of children with 
persistent hypertension despite lifestyle modification when the echocardiogram is normal. The 
CPG does advise ongoing BP monitoring every 3 to 6 months with reinforcement of lifestyle 
changes. When it is clear that lifestyle modification fails to lower BP in a given hypertensive 
child, pharmacologic therapy is indicated. Other factors to be considered in treatment decisions 
are the presence of co-morbidities commonly associated with hypertension including 
dyslipidemia and obstructive sleep apnea. The presence of multiple risk factors can support a 
move to pharmacologic treatment when there has been an insufficient or no response to lifestyle 
modification.   
 
Since the 2004 Fourth Report, clinical trial data on safety and efficacy have been 
obtained in children for newer antihypertensive drugs; and an updated list of recommended drug 
doses in children is provided in the 2017 CPG. Drug classes that are recommended for initial 
drug treatment of pediatric patients with primary hypertension include angiotensin converting 
enzyme inhibitors (ACE-I), angiotensin receptor blockers (ARB), long-acting calcium channel 
blockers (CCB), or thiazide diuretics.  For patients with chronic kidney disease, diabetes, or 
proteinuria, the 2017 CPG strongly recommends an ACE-I or ARB as the initial drug treatment.  
Since the 2004 Fourth Report, new data demonstrate that hypertensive TOD can be detected at 
BP levels <95th percentile, and BP reduction to below the 90th percentile can reverse LVH.  
Therefore, the treatment goal recommended by the 2017 CPG is systolic and diastolic BP <90th 
percentile or <130/80 mm Hg, whichever is lower (based on office BP measurements). An 
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 9 
exception to this treatment goal is the BP target for children with chronic kidney disease where 
there is strong clinical trial data that treatment with an ACE-I to a target of <50th percentile of 
mean 24-hour ambulatory blood pressure reduces the rate of decline in kidney function.13 
 
The 2017 CPG is a large document that was developed according to the strict evidence based 
approach recommended by the NHLBI. In addition, it is the first pediatric hypertension guideline 
in which the adolescent age period is largely aligned with the new adult hypertension CPG. A 
review of the extensive literature related to BP and hypertension in childhood published since 
2004 resulted in several modifications of recommendations on management of elevated BP and 
hypertension in childhood. While the 2017 CPG will provide guidance on achieving optimal BP 
management throughout childhood, there remain many unanswered questions that require 
further research. It is expected that acquisition of new evidence in the future will direct 
subsequent CPG updates and modifications.    
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